Diagnodus Ltd
Registered name: DIAGNODUS LTD
Diagnodus Ltd made £0 revenue and a £10.5k loss in the year to 30 Apr 2025.
Diagnodus Ltd’s revenue was £0 in the year to 30 Apr 2025, with a loss of £10.5k and 2 employees. The company is classified under “research and experimental development on biotechnology” and is based in Cambridge; we hold 4 years of its filed accounts.
- Status
- Active - Proposal to Strike off
- Location
- Cambridge, East of England
- Age
- 15 yrs · since 2011
- Type
- Private Limited Company
Key figures
Badges are automated estimates derived from the filed figures — not statements of fact about the company.
Financial history
| Year to | 30 Apr 2022 | 30 Apr 2023 | 30 Apr 2024 | 30 Apr 2025 |
|---|---|---|---|---|
| Disclosure | Full P&L | Full P&L | Full P&L | Full P&L |
| Profit & loss | ||||
| Revenue (turnover) | £0 | £0 | £0 | £0 |
| Profit after tax | £4.6k | −£10.8k | −£11.7k | −£10.5k |
| Profit (best available) | £4.6k | −£10.8k | −£11.7k | −£10.5k |
| Staff costs | £28.4k | £8.8k | £9.7k | £9k |
| Employees (average) | — | 2 | 2 | 2 |
| Ratios | ||||
| Profit margin | — | — | — | — |
| Revenue per employee | — | £0 | £0 | £0 |
| Profit per employee | — | −£5.4k | −£5.9k | −£5.3k |
| Growth (year on year) | ||||
| Profit growth | — | ▼333.2% | — | — |
| Headcount growth | — | — | 0% | 0% |
| Balance sheet — indirect signals, not revenue | ||||
| Net assets | −£111k | −£129k | −£146k | −£161k |
| Fixed assets | £5.4k | £4.3k | £3.4k | £2.7k |
| Current assets | £9.6k | £904 | £473 | £112 |
| Source | FullAccounts · bulk data Dec 2023 | FullAccounts · bulk data Dec 2023 | FullAccounts · bulk data Dec 2024 | FullAccounts · bulk data Dec 2025 |
How the business works
- Profit margin
- —
- Profit ÷ revenue.
- Gross margin
- —
- Gross profit ÷ revenue. High for software and services.
- Revenue per employee
- £0
- Revenue ÷ average employees.
- Profit per employee
- −£5.3k
- Profit ÷ average employees.
- Cash conversion
- —
- Cash generated from operations ÷ operating profit. Needs a cash-flow statement.
- Fixed assets ÷ revenue
- —
- Capital intensity. Low = capital-light, cheaper to start.
- Deferred income ÷ revenue
- —
- Customers paying upfront (subscriptions, deposits). Approximate when combined with accruals.
- Debtors ÷ revenue
- —
- Money owed by customers. Low = customers pay quickly.
Balance-sheet signals
Year-on-year changes in filed balance-sheet items. They can hint at momentum (or investment) but are not revenue or profit and must not be read as such.
- Net assets
- —
- Now −£161k
- Cash at bank
- —
- Now —
- Headcount
- 0%
- Now 2
- Deferred income
- —
- Now —
- Fixed assets
- ▼20%
- Now £2.7k
Similar profitable businesses
- Astex Therapeutics LimitedCambridge · Research and experimental development on biotechnology
- Revenue
- £404m
- Profit
- £283m
- Staff
- 183
- Amphista Therapeutics LimitedCambridge · Research and experimental development on biotechnology
- Revenue
- £33.9m
- Profit
- £19.8m
- Staff
- 56
- Charles River U.K. LimitedKent · Research and experimental development on biotechnology
- Revenue
- £22.2m
- Profit
- £18.8m
- Staff
- 129
- Qiagen Manchester LimitedManchester · Research and experimental development on biotechnology
- Revenue
- £53.7m
- Profit
- £11.8m
- Staff
- 239
- Alchemab Therapeutics LtdLondon · Research and experimental development on biotechnology
- Revenue
- £30m
- Profit
- £8.3m
- Staff
- 55
- Ligand UK Development LimitedLondon · Research and experimental development on biotechnology
- Revenue
- £8.7m
- Profit
- £6m
- Staff
- —
Sources
Latest figures from FullAccounts for the year to 30 Apr 2025 (profit −£10.5k), from the Companies House accounts bulk data published Dec 2025. Spotted an error? Request a correction.
Contains public sector information from Companies House licensed under the Open Government Licence v3.0. Data from Companies House, © Crown copyright. View the licence.